MilliporeSigma lands exclusive 5-year deal to test Genetix Biotherapeutics gene therapies
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
